Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma

被引:55
作者
Bradford, CR
Wolf, GT
Carey, TE
Zhu, SB
Beals, TF
Truelson, JM
McClatchey, KD
Fisher, SG
机构
[1] Univ Michigan, Ctr Med, Dept Otolaryngol Head & Neck Surg, Ann Arbor, MI 48109 USA
[2] Dept Vet Affairs Med Ctr, Ann Arbor, MI USA
[3] SW Texas State Univ, San Marcos, TX 78666 USA
[4] Loyola Univ, New Orleans, LA 70118 USA
关键词
D O I
10.1016/S0194-5998(99)70052-5
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
OBJECTIVE: A systematic retrospective study of the largest randomized trial of induction chemotherapy and radiation for advanced laryngeal cancer was undertaken to determine whether specific tumor or biologic factors were predictive of chemotherapy response, organ preservation, or survival. METHODS: The variables analyzed included clinical and histologic factors, immunohistochemical expression of proliferating cell nuclear antigen and p53, and adjusted DNA index measurements, Variables were evaluated for correlation with outcomes of tumor response, organ preservation, and survival. RESULTS: Multivariate analysis revealed that the best predictor of complete response to induction chemotherapy was low T class. The full multivariate model for predicting larynx preservation in patients treated with induction chemotherapy plus radiation shows that T class, p53 overexpression, and elevated proliferating cell nuclear antigen index were independent predictors of successful organ preservation. CONCLUSION: These predictive markers should be included in future clinical trials of advanced laryngeal cancer to determine their usefulness prospectively.
引用
收藏
页码:534 / 538
页数:5
相关论文
共 15 条
[1]  
BOURHIS J, 1994, LARYNGOSCOPE, V104, P468
[2]   OVEREXPRESSION OF P53 PREDICTS ORGAN PRESERVATION USING INDUCTION CHEMOTHERAPY AND RADIATION IN PATIENTS WITH ADVANCED LARYNGEAL-CANCER [J].
BRADFORD, CR ;
ZHU, SB ;
WOLF, GT ;
POORE, J ;
FISHER, SG ;
BEALS, T ;
MCCLATCHEY, KD ;
CAREY, TE ;
HONG, WK ;
URBA, S ;
ENDICOTT, JW ;
CLOSE, L ;
FISHER, SR ;
TOOHILL, RJ ;
KARP, D ;
MILLER, DM ;
CHEUNG, NK ;
WEAVER, A ;
HILLEL, AD ;
SPAULDING, M ;
CHANG, BK ;
DOUGHERTY, B ;
DECONTI, R ;
GAREWAL, H ;
FYE, C .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1995, 113 (04) :408-412
[3]   NEOADJUVANT CHEMOTHERAPY AND RADIOTHERAPY IN LARYNX PRESERVATION [J].
DIMERY, IW ;
KRAMER, AM ;
CHOKSI, AJ ;
HONG, WK .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1989, 12 (02) :173-177
[4]   DNA CONTENT AND TUMOR RESPONSE TO INDUCTION CHEMOTHERAPY IN PATIENTS WITH ADVANCED LARYNGEAL SQUAMOUS-CELL CARCINOMA [J].
GREGG, CM ;
BEALS, TE ;
MCCLATCHY, KM ;
FISHER, SG ;
WOLF, GT .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1993, 108 (06) :731-737
[5]  
JACOBS C, 1987, CANCER, V60, P1178, DOI 10.1002/1097-0142(19870915)60:6<1178::AID-CNCR2820600604>3.0.CO
[6]  
2-S
[7]  
JAKOBSSON PA, 1973, ACTA RADIOL THER PHY, V12, P1
[8]   Larynx preservation in pyriform sinus cancer: Preliminary results of a European organization for research and treatment of cancer phase III trial [J].
Lefebvre, JL ;
Chevalier, D ;
Luboinski, B ;
Kirkpatrick, A ;
Collette, L ;
Sahmoud, T .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (13) :890-899
[9]   TUMOR RESPONSE, TOXICITY, AND SURVIVAL AFTER NEOADJUVANT ORGAN-PRESERVING CHEMOTHERAPY FOR ADVANCED LARYNGEAL CARCINOMA [J].
SPAULDING, MB ;
FISCHER, SG ;
WOLF, GT ;
HONG, WK ;
URBA, S ;
ENDICOTT, JW ;
CLOSE, L ;
FISHER, SR ;
TOOHILL, RJ ;
KARP, D ;
MILLER, D ;
CHEUNG, NK ;
WEAVER, A ;
HILLEL, AD ;
SPAULDING, M ;
CHANG, BK ;
DOUGHERTY, B ;
DECONTI, R ;
GAREWAL, H ;
FORASTIERE, A ;
THORNTON, A ;
CALLAWAY, E ;
BEALS, T ;
GREENBERG, H ;
HOLLIMAN, D ;
LYMAN, G ;
SCHAEFER, S ;
COX, J ;
MIDDLETON, R ;
ASKEW, B ;
BRANTLEY, A ;
LEOPOLD, KA ;
WEINBURG, JB ;
LETTINGA, JW ;
HAAS, CD ;
KAPLAN, M ;
BYHARDT, RW ;
CORLEW, MM ;
CAMPBELL, B ;
VAUGHAN, C ;
WILLETT, B ;
WALSH, M ;
URIST, M ;
KIM, R ;
FAUCETT, R ;
PARK, Y ;
OHANIAN, M ;
KAUFMAN, R ;
KISH, J ;
EDELSTEIN, MB .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (08) :1592-1599
[10]  
TRUELSON JM, 1992, CANCER, V70, P56, DOI 10.1002/1097-0142(19920701)70:1<56::AID-CNCR2820700110>3.0.CO